BioSpace News Archive

CLEC-1, novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation. BiCKI ® -IL-7, bifunctional therapy targeting PD-1 and IL-7 to sustain exhausted T cell function and to disarm Treg suppressive activity.

Manhattan Scientifics Inc. invested $30 million and a 10-year effort to commercialize the Imagion Biosystems super early, non- invasive, non-radioactive Cancer diagnostic, now “partnered” with MD Anderson Cancer Center, Houston.

ZIVO Bioscience, Inc. ( OTCQB: ZIVO ), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and additive product candidates originally derived from proprietary algal cultures, announces that CEO Andrew A. Dahl will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021.

With The GIANT Company’s Support, CHOP’s Second-generation Food Pharmacy Will Serve Patient Families at its West Philadelphia Primary Care Center

Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced the addition of Mary Haak-Frendscho, Ph.D., to the Board of Directors.

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced its audited financial results for the fourth quarter and full year ended December 31, 2020.

Full Year Net Product Sales of $93.5 Million; Full Year Pro-Forma Revenue of $119.2 Million in Line with Guidance

CalciMedica Inc. (“CalciMedica” or the “Company”), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced it has secured a $21 million Series D financing led by Quark Venture LP and GHS Fund (Quark Venture LP and GF Securities) and joined by previous investors,

Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom of NVX–CoV2373, the company’s vaccine candidate.

Akerna (Nasdaq: KERN), an enterprise software, leading compliance technology provider and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), will report financial results for the quarter ended December 31, 2020, on Monday, March 22, 2021.